{"id":"NCT03417102","sponsor":"Genzyme, a Sanofi Company","briefTitle":"A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors","officialTitle":"ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-02-14","primaryCompletion":"2020-11-25","completion":"2021-06-23","firstPosted":"2018-01-31","resultsPosted":"2021-12-21","lastUpdate":"2022-03-28"},"enrollment":60,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia A","Hemophilia B"],"interventions":[{"type":"DRUG","name":"fitusiran","otherNames":[]},{"type":"DRUG","name":"Bypassing agents","otherNames":[]}],"arms":[{"label":"Bypassing Agents (BPA) On-demand","type":"ACTIVE_COMPARATOR"},{"label":"Fitusiran 80 mg Prophylaxis","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to determine the frequency of bleeding episodes in participants receiving fitusiran as prophylactic treatment of hemophilia compared to participants who were assigned to continue with their regular medication. In addition, the study assessed safety, quality of life, pharmacodynamics (PD), and pharmacokinetics (PK).","primaryOutcome":{"measure":"Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period","timeFrame":"From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest","effectByArm":[{"arm":"Bypassing Agents (BPA) On-demand","deltaMin":18.071,"sd":null},{"arm":"Fitusiran 80 mg Prophylaxis","deltaMin":1.666,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":11},"locations":{"siteCount":58,"countries":["United States","Australia","Canada","China","France","Germany","India","Italy","Japan","Malaysia","South Africa","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["37003287","35114155","34922648"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":19},"commonTop":["Alanine Aminotransferase Increased","Aspartate Aminotransferase Increased","Headache","Upper Respiratory Tract Infection","Gamma-Glutamyltransferase Increased"]}}